Literature DB >> 28121236

Rapid response to a college outbreak of meningococcal serogroup B disease: Nation's first widespread use of bivalent rLP2086 vaccine.

Theresa M Fiorito1, Suzanne Bornschein2, Alysia Mihalakos3, Catherine M Kelleher2, Nicole Alexander-Scott4, Koren V Kanadanian5, Patricia Raymond3, Kenneth Sicard2, Penelope H Dennehy1.   

Abstract

OBJECTIVE: To outline the reasoning behind use of bivalent rLP2086 in a Rhode Island college meningococcal B disease outbreak, highlighting the timeline from outbreak declaration to vaccination clinic, emphasizing that these two time points are <3 days apart. PARTICIPANTS: Staff, faculty, and students at College X eligible for vaccination.
METHODS: An outbreak response was initiated, advantages/disadvantages of available MenB vaccines were discussed, and a vaccination clinic was coordinated.
RESULTS: Bivalent rLP2086 was chosen as the vaccination intervention. We achieved a 94% coverage rate for the first dose. To date, this intervention has prevented further cases of Neisseria meningitidis serogroup B disease at College X.
CONCLUSIONS: The close, efficient collaboration of public health stakeholders and College X led 94% of the eligible population to be safely vaccinated with at least one dose of bivalent rLP2086. This outbreak marked the first time bivalent rLP2086 was effectively used as an intervention response.

Entities:  

Keywords:  Bivalent rLP2086; Neisseria meningitidis; meningococcal B disease; vaccination

Mesh:

Substances:

Year:  2017        PMID: 28121236     DOI: 10.1080/07448481.2017.1285772

Source DB:  PubMed          Journal:  J Am Coll Health        ISSN: 0744-8481


  5 in total

Review 1.  Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak control.

Authors:  Paul Balmer; Laura J York
Journal:  Ther Adv Vaccines Immunother       Date:  2018-06-21

2.  Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.

Authors:  Elizabeth M La; Sandra E Talbird; Koren V Kanadanian; Liping Huang; Joel Fain; Amit Srivastava
Journal:  Hum Vaccin Immunother       Date:  2019-01-16       Impact factor: 3.452

3.  Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.

Authors:  Eduardo Lujan; Elizabeth Partridge; Serena Giuntini; Sanjay Ram; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

4.  University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013-2018.

Authors:  Heidi M Soeters; Lucy A McNamara; Amy E Blain; Melissa Whaley; Jessica R MacNeil; Susan Hariri; Sarah A Mbaeyi
Journal:  Emerg Infect Dis       Date:  2019-03       Impact factor: 6.883

5.  Experience implementing a university-based mass immunization program in response to a meningococcal B outbreak.

Authors:  Blair Capitano; Krista Dillon; Andre LeDuc; Bruce Atkinson; Cynthia Burman
Journal:  Hum Vaccin Immunother       Date:  2019-01-08       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.